Capital Building in Washington DC


To improve patient care, ASCO advocates for increased federal funding for research, greater health care access, value in cancer care, and payment reform.

  • Misguided Most Favored Nation Model Will Limit Access to Care

    The Association for Clinical Oncology opposes this model, which outlines a mandatory demonstration. Under the guise of a demonstration project, this plan imposes a new reimbursement model on cancer care without evidence that it can lower costs without negatively impacting Medicare beneficiaries.

    Learn More
  • AMA Delegates Take Action from Home

    From November 13- 17, Association for Clinical Oncology (ASCO) delegates participated in the American Medical Association’s (AMA) House of Delegates (HOD) Meeting virtually. This year delegates focused on racism, home infusion, and co-pay accumulators.

    Stay Informed
  • Most Favored Nation Model Interim Rule Released

    The Centers for Medicare & Medicaid Services (CMS) released the Most Favored Nation (MFN) Model Interim Final Rule with Comment Period (IFC). The MFN Model would be mandatory, last for seven years (January 1, 2021 – December 31, 2027), and initially affect 50 drugs reimbursed under Medicare Part B. 

    Read Now

Random Quote

"As medical professionals and as a Society, we must all continue to evolve and transform cancer care and research with each new discovery."
Julie M. Vose, MD, MBA, FASCO
ASCO President, 2015-16